Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: LonZim, Lees Foods, blinkx ...

Wed, 27th May 2009 07:59

Zimbabwe-focused investment company LonZim said it is well-placed to benefit from any upturn in the southern African country's economy after investing in several sectors in the six months to February 28.The company posted a pre-tax loss of £911,000 as it invested in telecoms, aviation and hotel sectors."We are positive that the investment potential in Zimbabwe remains strong and that Zimbabwe has a very bright future as it looks to re-establish its presence as one of the major economies on the African continent," said chairman David Lenigas.Scottish cake and sweet supplier Lees Foods saw profits fall sharply in 2008 as it felt the impact of the collapse of the retail chain Woolworths and high raw material, power and distribution costs.Underlying pre-tax profits fell to £402,000 from £721,000 the previous year even as turnover climbed 8% to £16.1m."The fall in profits was primarily a result of a bad debt provision of £69,000 which was owed to the company by Woolworths and a significant increase in raw materials, power and distribution costs," Lees said.The board is recommending the dividend be maintained at 6.7p a share.Video search engine specialist blinkx has signed an agreement with US sport site FOXSports.com to add almost 1,000 video clips of sporting contests to its searchable video library. Globus Maritime saw gross revenues of $11.8m against $24m in the same period last year, while EBITDA was $7m against $18.8m.AIM-listed Africa-focused gas company Gasol has successfully raised £1m through a placing of shares with two of its principal shareholders, African Gas Development Corporation and Afren.Shares in Vyke Communications were marked lower Wednesday after the company said it issued 0.26m shares to settle supplier invoices totalling 1.75m Norwegian kroner. The newly issued shares represent 0.4% of Vyke's existing issued share capital.Smoker's cough treatment specialist Synairgen has raised £6.35m through a placing and subscription at 17p per share. The proceeds will finance two planned Phase IIa inhaled interferon beta studies in asthma and COPD.Bus maker Optare slipped into a loss £12m in 2008 reflecting costs of integrating two new businesses in difficult trading conditions. Turnover for the year was £49.2m (pro forma £82.4m) and loss from operations was £4.0m (pro forma £3.0m). Programme maker Shed Media has appointed Heather Rabbatts, Millwall FC's executive deputy chairman, as its new chairman. Coline McConville, who sat on the board of HBOS until early this year, and Marc Watson, from BT, are also joining as non-execs. Celebrity agent Formation Group saw profit before tax edge up to £1.83m in the six months ended 28 February from £1.76m a year ago on revenue from continuing operations of £18.8 versus £12.8m last time.The shares rallied yesterday after the group, whose clients include Simon Cowell and TV presenters Ant and Dec, confirmed it has received indications of interest from private equity group Gresham over 'certain parts' of the business. IFA Cavanagh's underlying profits fell to £779,000 (2007: £1.61m) on revenue of £17.5m (2007: £16.6m)in 2008. " Against a backdrop of what has probably been the most volatile period experienced in the financial markets since the 1930s, I consider this to be a satisfactory performance," chairman Paul Sinnet said.Powered glass specialist Romag posted an underlying loss of £1.3m in the half -year to March in what the company describes as the toughest conditions it has seen for 60 years. Unless conditions turned in the next few weeks it is unlikely it will be able to repeat the strong performance in sales and profits achieved in the second half of last year. Interim sales were 12% down at £10.2m, though a £2.7m currency hedging gain enabled it post a £1.1m profit.
More News
20 Jan 2021 21:16

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

Read more
13 Jan 2021 10:24

Synairgen Doses First Patient In Covid-19 Treatment Trial

Synairgen Doses First Patient In Covid-19 Treatment Trial

Read more
11 Jan 2021 20:54

COVID SCIENCE-COVID-19 patients still have symptoms 6 months later; interferon may be helpful treatment after all

By Nancy LapidJan 11 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Half a year later, COVID-19 pat...

Read more
18 Dec 2020 12:08

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

Read more
18 Dec 2020 11:06

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Read more
18 Dec 2020 10:29

Synairgen makes solid progress with Covid-19 treatment

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its phase 3 trial design evaluating SNG001 as a treatment for patients with Covid-19 on Friday, as well as positive progress on its regulatory path.

Read more
18 Nov 2020 13:59

finnCap Interim Profit More Than Doubles; Chair To Step Down

finnCap Interim Profit More Than Doubles; Chair To Step Down

Read more
13 Nov 2020 14:28

Synairgen surges on positive results for Covid-19 treatment

(Sharecast News) - Synairgen shares surged on Friday after data from trials of its inhaled Covid-19 treatment, SNG001, published in The Lancet Respiratory Medicine, showed positive results in hospitalised patients.

Read more
13 Nov 2020 10:24

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Read more
2 Nov 2020 20:03

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

Read more
15 Oct 2020 11:39

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Read more
14 Oct 2020 18:02

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

Read more
29 Sep 2020 12:14

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Read more
9 Sep 2020 16:04

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

Read more
9 Sep 2020 12:23

Synairgen files for another patent on 'SNG001'

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its intellectual property for the wholly-owned inhaled interferon beta asset 'SNG001' on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.